Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider James Hamilton Sells 15,000 Shares

Key Points

• Insider James Hamilton sold 15,000 shares of Arrowhead Pharmaceuticals for $450,000, reducing his ownership by 6.07% to 232,122 shares valued at approximately $6.96 million.
• The company's stock price recently hit $29.42, with a significant range over the past year between $9.57 and $31.13.
• Arrowhead Pharmaceuticals reported a loss of $1.26 EPS for the last quarter, missing expectations, and analysts predict a year-end EPS of -$2.42.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) insider James Hamilton sold 15,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, September 12th. The stock was sold at an average price of $30.00, for a total transaction of $450,000.00. Following the transaction, the insider directly owned 232,122 shares of the company's stock, valued at $6,963,660. This represents a 6.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Arrowhead Pharmaceuticals Stock Performance

ARWR traded up $0.75 during midday trading on Tuesday, hitting $29.42. The company had a trading volume of 1,992,359 shares, compared to its average volume of 2,713,601. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $31.13. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The stock's 50 day moving average price is $20.23 and its 200 day moving average price is $16.59.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same period in the previous year, the firm posted ($1.38) earnings per share. As a group, analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on ARWR shares. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. Chardan Capital reiterated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 2nd. B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, August 11th. Finally, Royal Bank Of Canada reduced their target price on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a report on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $43.14.

Institutional Trading of Arrowhead Pharmaceuticals

Large investors have recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Arrowhead Pharmaceuticals by 138.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock valued at $60,962,000 after buying an additional 2,774,933 shares during the period. Marshall Wace LLP boosted its position in shares of Arrowhead Pharmaceuticals by 3,507.8% in the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company's stock worth $34,065,000 after purchasing an additional 2,096,238 shares during the period. Norges Bank purchased a new position in shares of Arrowhead Pharmaceuticals in the second quarter worth $30,414,000. Vanguard Group Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 8.4% in the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock worth $168,201,000 after buying an additional 1,018,273 shares in the last quarter. Finally, Aberdeen Group plc raised its stake in Arrowhead Pharmaceuticals by 138.4% during the first quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company's stock valued at $13,668,000 after purchasing an additional 622,752 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.